Specialty Pharmacy

Belimumab was the first and only approved biologic for active systemic lupus erythematosus and lupus nephritis in more than 50 years, including for pediatric patients.

Specialty medication has grown to about 55% of net spending, which is up by 28% since 2011 mostly driven by autoimmune diseases and oncology.

Availability of TNF-alpha inhibitor biosimilars in Southern European markets led to lowered costs within the drug class, even after an increased consumption volume for these therapies.

The need for pharmacists to return to a more clinically-focused role became apparent as the COVID-19 pandemic revealed gaps in patient access to care across the country.

In the United States, 91% of states had lower rates of targeted therapy use than expected.

Amjevita is approved for all indications of reference Humira except for hidradenitis suppurativa.

Patients who received first-line ICI showed a significant improvement in progression-free survival (PFS) and overall survival (OS) compared to chemotherapy treatment.

At leukapheresis, a low frequency of differentiated CD3+CD27-CD28--T cells can indicate favorable response to CAR T-cell therapy.

Zolbetuximab treatment reduced risk of death by 25% compared to placebo.

NRTIs TAF and TDF are increasingly being used as preexposure prophylaxis (PrEP) to prevent HIV around the world.

OR-449 is being developed for both adult and pediatric patients with adrenocortical carcinoma, as well as other cancers known to express a high level of steroidogenic factor-1.

Sarah McDonald, cancer survivor and author of The Cancer Channel, discusses her experience battling 2 different unrelated cancers and the value oncology pharmacists could have provided with a greater presence on her care team.

Inequities were also apparent between those who saw and did not see neurologists, analysis shows.

Deucravacitinib is an oral, selective, allosteric tyrosine kinase 2 inhibitor that inhibits cytokine signaling in psoriasis pathogenesis.

The stool-test is the first-of-its-kind to detect CRC in adults aged 45 to 49 years, with a premarket approval submission planned to be sent to the FDA early in 2023.

Research shows that some unsuccessful switches from reference products to biosimilars may be attributed to patient perceptions of reduced efficacy and safety.

The head of the CAR T cell antibody can recognize and target the growth factor in its tumor microenvironment.

YLB113 (Nepexto) produced significantly lower injection site reactions and injection site erythema compared with etanercept in patients with rheumatoid arthritis.

The analysis found a median progression-free survival of 14.2 months in the ripretinib arm, compared with 1.5 months in the sunitinib arm.

Joseph Araujo, Chief Scientific Officer at Mindset Pharma, sat down to discuss natural vs. synthetic psychedelics.

Patient financial/co-pay assistance is usually a component of providing infusion services and practices need to make sure it’s carefully managed to prevent financial hardship to patients.

Pharmacists report a myriad of reasons for joining the profession, including the connections they can build with patients.

Viral infections can plague patients who have undergone stem cell transplantation.

Analysis indicates that Acadia Pharmaceuticals Inc’s pimavanserin is the only FDA-approved medication for the treatment of delusions and hallucinations associated with PDP.

In the geographical region of a recent study, data showed melanoma cause high mortality rates in relation to incidence.

Digitizing hub processes can create an efficient and effective tech-driven patient access strategy speeding access to lifesaving therapies.

If approved, glofitamab will treat the most aggressive type of non-Hodgkin lymphoma.

Ublituximab-xiiy from TG Therapeutics Inc is the first anti-CD20 monoclonal antibody approved for individuals with RMS that is administered as a 1-hour infusion after the starting dose.